Connect Sign In
ARUP has gained a Conformité Européenne (CE) mark for AAV5 DetectCDx™ single-site use. The test will aid in determining the eligibility of non-U.S. patients for a new hemophilia A gene therapy.
During a networking event cohosted by ARUP, leaders in the life sciences advocated for more returnships to help those who have taken time off ease back into careers in STEM.
ARUP Blood Services has announced the rollout of its Whole Blood Titan program, which will encourage donations of low-titer, type O blood that is vital to saving lives in emergency situations.
A platform clients use to reduce testing waste, lower cost per test, and improve patient safety has won the prestigious Choosing Wisely Champion Award from the American Society for Clinical Pathology.
The FDA’s newly proposed rules would regulate all in vitro diagnostic products as medical devices if enacted. ARUP believes additional FDA oversight would disrupt the diagnostic testing market.
New ARUP Institute for Research and Innovation in Diagnostic and Precision Medicine™ will improve patient lives by advancing groundbreaking diagnostic and prognostic technologies.
Forbes magazine has listed ARUP as one of the 2023 Best Employers by State based on employer recommendations from employees and others in Utah in a recent survey conducted by Statista.
Ragan Communications has recognized an ARUP program that helps staff improve their health through exercises that treat and prevent injuries that can result from the repetitive nature of work in a lab.
ARUP is gearing up for the launch of a new hematopathology webinar to be hosted by Madhu Menon, MD, PhD, FCAP. Other ARUP experts will join Menon to discuss timely issues in hematopathology testing.
A novel event organized by ARUP’s Patent Committee aimed to highlight creative solutions that may not lead to patents but still advance laboratory medicine and improve patient care.
ARUP researchers and medical directors will join industry leaders at AACC 2023 to share their expertise on laboratory stewardship, workforce needs, automation, and more.
ARUP Laboratories has received FDA approval for its companion diagnostic immunoassay, AAV5 DetectCDx™, which helps determine patient eligibility for a new gene therapy for severe hemophilia A.
